Zur Kurzanzeige

dc.contributor.authorArias Vallejo, Francisco Javier 
dc.contributor.authorSantos García, María Mercedes 
dc.contributor.authorIbáñez Fonseca, Arturo
dc.contributor.authorPiña, María Jesús
dc.contributor.authorSerrano Dúcar, Sofía
dc.date.accessioned2017-04-03T10:44:08Z
dc.date.available2017-04-03T10:44:08Z
dc.date.issued2016
dc.identifier.citationCurrent Drug Targets, 2016, vol. 17, pages 1-20es
dc.identifier.issn1389-4501es
dc.identifier.urihttp://uvadoc.uva.es/handle/10324/22951
dc.description.abstractDrug delivery systems that are able to control the release of bioactive molecules and designed to carry drugs to target sites are of particular interest for tissue therapy. Moreover, systems comprising materials that can respond to environmental stimuli and promote self-assembly and higher order supramolecular organization are especially useful in the biomedical field. Suitable biomaterials for this purpose include elastin-like recombinamers (ELRs), a class of proteinaceous polymers bioinspired by natural elastin and designed usingrecombinant technologies. The self-assembly and thermoresponsive behaviour of these systems, along with their biodegradability, biocompatibility and well-defined composition as a result of their tailor-made design, make them particularly attractive for drug delivery.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherBentham Sciencees
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.subject.classificationElastin-like Recombinamerses
dc.subject.classificationDrug deliveryes
dc.subject.classificationSmart systemses
dc.subject.classificationSelf-Assemblyes
dc.subject.classificationHydrogelses
dc.subject.classificationNanocarrierses
dc.titleElastin-like recombinamers as smart drug delivery systemses
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.doi10.2174/1389450117666160201114617es
dc.peerreviewedSIes
dc.description.projectEste trabajo forma parte de Proyectos de Investigación financiados por la Comisión Europea a través del Fondo Social Europeo (FSE) y el Fondo Europeo de Desarrollo Regional (ERDF), por el del MINECO (MAT2013-41723R, MAT2013-42473-R, MAT2012-38043 y PRI-PIBAR-2011-1403), la Junta de Castilla y León (VA049A11, VA152A12 y VA155A12) y el Instituto de Salud Carlos III bajo el Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León.es


Dateien zu dieser Ressource

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige